Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 38

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 38
---
 has indicated its belief that there is a high
probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are
applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers
buy our common stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect
on the market for and price of our common stock.

Future sales of shares by existing stockholders
could cause the Company’s stock price to decline. 

If existing stockholders of the Company sell, or indicate
an intention to sell, substantial amounts of the Company’s common stock in the public market, the trading price of the common stock
could decline significantly. After the Reverse Merger, shareholders of Private Mosaic currently own a majority of the fully diluted shares
of common stock outstanding. In addition, our shareholders are not restricted in the price at which they can sell their shares. Shares
sold at a price below the current market price at which our common stock is trading may cause the market price of our common stock to
decline.

We expect our stock price to be volatile, and the market price of our
common stock may drop unexpectedly. 

The market price of our common stock could be subject
to significant fluctuations. For instance, during the year ended December 31, 2024, the low and high trading prices of our common stock
ranged from $0.10 to $1.13 per share. Market prices for securities of early-stage pharmaceutical, biopharmaceutical, and other life sciences
companies have historically been particularly volatile.

 22 

Some of the factors that may cause the market price
of our common stock to fluctuate include:

    ·
    our limited cash position and our immediate need for additional capital;

    ·
    potential results from preclinical testing and clinical trial results, and our ability to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;

    ·
    issues in manufacturing these product candidates;

    ·
    the entry into, or termination of, key agreements;

    ·
    the initiation of, material developments in, or conclusion of litigation to enforce or defend intellectual property rights or defend against the intellectual property rights of others;

    ·
    announcements by competitors of new commercial products, clinical progress or the lack thereof, significant contracts, or commercial relationships;

    ·
    the introduction of